Shinobi Therapeutics Funding & Investors

Shinobi Therapeutics focuses on creating hypoimmune CD8αβ iPS-T cells that work with the immune system to treat cancer and other diseases. The company utilizes advanced immune evasion technology to enhance the effectiveness and accessibility of cell therapies. Shinobi's innovative approach aims to reduce costs and improve patient outcomes through durable responses and redosing capabilities.